NEW YORK (CNN/Money) - If you are looking to enhance your appearance, don't rely on late-night infomercials for the answer.
The Federal Trade Commission clamped down on the companies that make and market Bloussant, a breast enhancement treatment; EnerX, a male virility product; and D-Snore, a snoring treatment, for making false and unsubstantiated promises about their products.
"Marketers must have rigorous scientific substantiation for the claims they make," said Howard Beales, director of the FTC's Bureau of Consumer Protection. "In this case, the claims were inflated, but the science just wasn't there."
According to a press release issued by the FTC, Bloussant claimed to stimulate breast cells to regenerate the growth process, thereby increasing the bustline by two cups, while D-Snore promised to reduce or eliminate snoring and mitigate sleep apnea symptoms through the use of a liquid mouth spray.
Regulators also challenged claims that EnerX, an herbal supplement designed to boost male potency, is safe and lacking in side effects because the product contained yohimbine, which is known to increase blood pressure and adversely interact with other medications.
Wellquest International Inc., the company that manufactures these products, has agreed to pay $3.2 million to settle the charges. Tony Hoffman Productions Inc., which produced many of Wellquest's advertisements and provided telemarketing services for their products, and Dr. Mark Buchfuhrer, who endorsed D-Snore, also settled FTC charges.